Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration

(2022) Niklas Mattsson-Carlgren et al.   NEUROLOGY

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

(2021) A. Leuzy et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

(2021) Oskar Hansson et al.   Alzheimers & Dementia

Biomarkers for neurodegenerative diseases

(2021) Oskar Hansson   NATURE MEDICINE

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy

(2021) Michel J. Grothe et al.   NEUROLOGY

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

(2021) Shorena Janelidze et al.   JAMA Neurology

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

(2021) Charlotte E Teunissen et al.   LANCET NEUROLOGY

Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET

(2020) Renaud La Joie et al.   Science Translational Medicine

The implications of different approaches to define AT(N) in Alzheimer disease

(2020) Niklas Mattsson-Carlgren et al.   NEUROLOGY

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

(2020) James D. Doecke et al.   Alzheimers Research & Therapy

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   Science Advances

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers

(2019) Gemma Salvadó et al.   Alzheimers Research & Therapy

Towards a unified protocol for handling of CSF before β-amyloid measurements

(2019) Shorena Janelidze et al.   Alzheimers Research & Therapy

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

Toward a Framework for Outcome-Based Analytical Performance Specifications: A Methodology Review of Indirect Methods for Evaluating the Impact of Measurement Uncertainty on Clinical Outcomes

(2019) Alison F. Smith et al.   CLINICAL CHEMISTRY

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

(2018) Suzanne E. Schindler et al.   Alzheimers & Dementia

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

(2018) Oskar Hansson et al.   Alzheimers & Dementia

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

(2018) Oskar Hansson et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements

(2018) Ulf Andreasson et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-β42 in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry

(2018) Magdalena Korecka et al.   JOURNAL OF ALZHEIMERS DISEASE

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

(2018) Renaud La Joie et al.   Alzheimers & Dementia

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Niklas Mattsson et al.   NEUROBIOLOGY OF AGING

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid

(2016) Tobias Bittner et al.   Alzheimers & Dementia

The use of a “gray zone” considering measurement uncertainty in pharmacological tests. The serum growth hormone stimulation test as an example

(2016) Juan Manuel Lazzati et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem

(2015) Christoffer Rosén et al.   Alzheimers & Dementia

Mild to moderate Alzheimer dementia with insufficient neuropathological changes

(2014) Alberto Serrano-Pozo et al.   ANNALS OF NEUROLOGY

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

(2012) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

(2012) A. D. Joshi et al.   JOURNAL OF NUCLEAR MEDICINE

National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach

(2011) Thomas J. Montine et al.   ACTA NEUROPATHOLOGICA

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Classification and basic pathology of Alzheimer disease

(2009) Charles Duyckaerts et al.   ACTA NEUROPATHOLOGICA

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

(2009) C. E. Teunissen et al.   NEUROLOGY